Background {#Sec1}
==========

Anesthesia care for patients in their seventies or eighties has an ever-growing presence in clinical practice given the demographic development in many industrialized countries. Variable degrees of cognitive decline are frequently observed after major surgery in elderly patients and have been defined as postoperative cognitive dysfunction (POCD) \[[@CR1]\]. Clinical studies have reported an incidence of POCD of up to 41% in surgical patients older than 60 years (Table [1](#Tab1){ref-type="table"}) \[[@CR2]\]. In many patients, this is a transient problem. But in some patients, cognitive deficits are long-term or permanent \[[@CR1], [@CR2]\]. POCD may also develop in younger patients \[[@CR3]\] and after minor surgery \[[@CR4]\]. The occurrence of POCD is associated with increased mortality and important socioeconomic consequences \[[@CR5]\].Table 1Incidence of POCD after noncardiac surgeryStudyPopulationTime for postoperative testPOCD rate (%)Moller et al. \[[@CR1]\]Patients ≥60 undergoing major abdominal, thoracic, or orthopedic surgery1 week and 3 months25.8 and 9.9%, respectivelyMonk et al. \[[@CR2]\]Patients \>60 undergoing minimally invasive, intraabdominal/thoracic, or orthopedic surgery1 week and 3 months41.4 and 12.7%, respectivelyJohnson et al. \[[@CR3]\]Patients 40--60 undergoing major abdominal or orthopedic surgery1 week and 3 months19.2 and 6.2%, respectivelyCanet et al. \[[@CR4]\]Patients \>60 undergoing minor surgery1 week and 3 months6.8 and 6.6%, respectively*POCD* postoperative cognitive dysfunction

The potential association between exposure to anesthesia and the development of dementia in elderly patients remains a controversial topic \[[@CR6], [@CR7]\]. So far, a direct association between surgery and long-term cognitive decline has not been established \[[@CR8]\]. The pathophysiology of POCD is poorly understood, and no preventive strategy or treatment has been described so far \[[@CR9]\]. A retrospective analysis of cohort data suggests that surgery may be associated with a decrease in brain volume \[[@CR10]\]; however, no analysis of a potential link between cerebral atrophy and cognitive functions was made. We would like to reproduce and verify these results and investigate a possible relationship with the postoperative cognitive performance in surgical patients.

The principal objective of this observational cohort study is to prospectively test the hypothesis whether major noncardiac surgery under sevoflurane-based general anesthesia is associated with a loss of cerebral grey matter in elderly patients. We also hypothesize that the degree of POCD correlates with the loss of grey matter in brain areas relevant for cognitive functions.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

This prospective, observational cohort study is being conducted at the University Hospital Basel, Switzerland. Study recruitment commenced in July 2015 and is expected to last for 36 months. The regional ethics committee (EC) approved the study prior to participant inclusion (Ethikkommission Nordwestschweiz, protocol: EKNZ 2014--155, 1 August 2014). The study was registered on clinicaltrials.gov (NCT02045004) on 22 January 2014 and on Kofam.ch (SNCTP000001751) on 21 April 2016.

Study population {#Sec4}
----------------

Two groups of study participants will be investigated in this prospective cohort study. Seventy patients aged ≥65 years undergoing major surgical procedures will be recruited for this study (Group 1). Thirty volunteers aged ≥65 years will be recruited as matched nonsurgical controls (Group 2).

### Recruitment and informed consent {#Sec5}

Study participants in the surgical group (Group 1) will be recruited as patients of the University Hospital Basel, Switzerland. Eligible patients are identified by screening the daily list of visits in the preoperative anesthesia clinic. They are either contacted personally on the same day, or by mail in a letter including participant information and a consent form. A follow-up phone call by an investigator will provide further information about relevant details of the study. Study participants in the nonsurgical control group (Group 2) will be recruited from an existing study subject registry established by the Memory Clinic at the Felix Platter Hospital, Basel, Switzerland. Nonsurgical controls are matched to surgical patients according to age, gender and level of education.

The study is conducted with written informed consent from all study subjects and is conducted with respect of the most recent version of the Declaration of Helsinki \[[@CR11]\]. Participants are informed that participation in the study is voluntary, and that they are free to withdraw at any time. Recruitment and consenting of study participants by members of the research team is in-line with Good Clinical Practice (GCP) \[[@CR12]\].

### Inclusion and exclusion criteria {#Sec6}

Study inclusion and exclusion criteria appear in Table [2](#Tab2){ref-type="table"}. All patients aged 65 years or older, American Society of Anesthesiologists' physical status I--III, who are scheduled from major elective surgery under general anesthesia at the University Hospital Basel, are eligible for study inclusion in Group 1. Further inclusion criteria comprise a home location suitable for testing, German as their first language, and an Instrumental Activities of Daily Living \[[@CR13]\] score ≥6. Participants in Group 2 are volunteers who present equal inclusion and exclusion criteria, without planned surgery.Table 2Study inclusion and exclusion criteriaCriterionScreening procedureInclusion criteria Age ≥65 yearsMedical record Home location suitable for testingMedical record German as a first languageMedical record or recruitment telephone call IADL score ≥6Baseline assessment ASA physical status I--IIIBaseline assessment Major elective surgery^a^Medical record Planned general anesthesia^a^Baseline assessmentExclusion criteria Cardiac surgery^a^Medical record Neurosurgery including carotid endarterectomy, or any type of surgery precluding postoperative testing^a^Medical record (Another) major surgery within the study timelineMedical record, recruitment telephone call or baseline interview General anesthesia up to 3 months prior to inclusionMedical record Baseline MMSE score \<24Baseline neuropsychological assessment Dementia criteria per DSM-5Baseline neuropsychological assessment Previous pathological cerebral imaging (if available)Medical record History of cerebral or cerebrovascular pathology, head trauma, neurodegenerative illness or epilepsyMedical record Chronic use of psychiatric medicationMedical record or baseline interview Alcohol or substance abuseMedical record or baseline interview History of chronic pain unrelated to the planned surgeryMedical record Chronic medical illness known to induce encephalopathyMedical record Any contraindication for MRI (e.g., pacemakers and other MRI-incompatible implantable device)Medical record, recruitment telephone call or baseline interview ClaustrophobiaMedical record, recruitment telephone call or baseline interview Incidentally diagnosed disease or unfavorable course of disease in participants who choose not to be informedAny study assessment Lack of informed consentRecruitment telephone call*ASA* American Society of Anesthesiologists, *DSM-5* Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, *IADL* Instrumental Activities of Daily Living, *MMSE* Mini-Mental State Examination^a^Not applicable for the nonsurgical control group

Outcomes {#Sec7}
--------

The primary endpoint of this study is the degree of change in hippocampal volume over time between patients with and patients without POCD. Other specific cerebral volumes measured are the lateral ventricles, the total grey matter volume, and regional cortical thickness. The secondary endpoint is the correlation between the change in cerebral volume and the change in cognitive function.

Study procedures {#Sec8}
----------------

Study-related procedures include a baseline multimodal assessment, intraoperative data acquisition and postoperative multimodal assessments on study visits scheduled 1 week, 3 months and 1 year after surgery. Figure [1](#Fig1){ref-type="fig"} shows the flow diagram for the study assessments on a time line.Fig. 1Flow diagram of study procedures

### Anesthetic management {#Sec9}

Anesthesia will be standardized. Intravenous propofol and fentanyl will be used for induction of general anesthesia, atracurium or rocuronium for neuromuscular blockade. Patients will be intubated and mechanically ventilated with an air/oxygen mixture to maintain an end-tidal carbon dioxide at 4.6 ± 0.6 kPa. Inhalational sevoflurane, intravenous fentanyl or remifentanil will be used to maintain anesthesia. Intraoperatively, the dose of anesthetics will be controlled using depth of anesthesia monitoring at a targeted bispectral index (BIS) of 40--60 and end-tidal sevoflurane concentration monitoring. Data will be downloaded directly from the patient monitor (IntelliVue™ MX800, Philips Healthcare, Zurich, Switzerland) and the anesthesia machine (Perseus™, Dräger, Liebefeld, Switzerland) on a personal computer using ICM+ software (Cambridge Enterprise Ltd, University of Cambridge, United Kingdom).

### Neuropsychological assessment {#Sec10}

The Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB) \[[@CR14]\], Trail Making Tests A and B \[[@CR15]\], and phonemic fluency (s-words) \[[@CR16]\] will be performed preoperatively, at 7 days, 3 months and 1 year postoperatively. Training of all study personnel and supervision of cognitive testing will be carried out by the Memory Clinic at Felix Platter Hospital. Cognitive functions will be quantified using the CERAD-NAB total score \[[@CR17]\], in its demographically-corrected form \[[@CR18]\]. A correction for short-term practice effects will be carried out based on previous work \[[@CR19]\]. Table [3](#Tab3){ref-type="table"} shows the neuropsychological subtests used in this study \[[@CR20]\]. The 15 variables resulting from neuropsychological assessment are converted into standard scores (z-scores) based on a normative sample \[[@CR21]\], and the z-score changes from baseline are calculated. POCD is diagnosed if the decline is \>1.0 standard scores in two or more of the 15 variables based on the diagnostic guideline for mild cognitive impairment and dementia related to Alzheimer's disease by the National Institute on Aging-Alzheimer's Association \[[@CR22]\] and the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) \[[@CR23]\]. Postoperative delirium is assessed using the Delirium Observation Screening scale \[[@CR24]\] and, if applicable, the Confusion Assessment Method \[[@CR25]\], administered 3 times daily until the fifth postoperative day.Table 3Subtests of the neuropsychological assessment battery used for diagnosis of POCDTest variableTest descriptionDomain testedCERAD-NAB word list-encodingTotal number of correctly learned words across three learning trials (number of words per trial = 10)Verbal episodic learningCERAD-NAB word list-delayed free recallTotal number of correctly remembered words after a delay following encodingVerbal episodic memoryCERAD-NAB word list-savingsProportion of correctly recalled words during delayed free recall relative to words learned in learning trial 3Verbal episodic memoryCERAD-NAB word list-discriminabilityRate of correctly recognized words from encodingVerbal episodic memoryCERAD-NAB word list-intrusion errorsTotal number of intrusions committed during word list-encoding and -delayed free recallExecutive functionsCERAD-NAB figures-copyCopy of four figures (circle, diamond, overlapping rectangles, cube)Visuospatial abilityCERAD-NAB figures-delayed recallNumber of correctly reproduced figures from figures-copy following a delayVisual memoryCERAD-NAB figures-savingsProportion correctly reproduced figures at figures-delayed recall relative to figures-copyVisual memorySemantic fluency-animalsNumber of animals produced within 1 minSemantic memoryBoston naming test (15-items)Number of spontaneously correctly named black and white line drawings (maximum = 15)LanguageTrail making test ATime required to connect circles numbered from 1 to 25 in ascending orderPsychomotor speedTrail making test BTime required to connect circles containing numbers (1--13) and letters (A-L) in ascending and alternating orderExecutive functionsPhonemic fluencyNumber of words starting with the letter S produced within 1 minExecutive functions*CERAD-NAB* Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery. Adapted from Mistridis et al. \[[@CR20]\]

### Other assessments {#Sec11}

Other assessment tools include the Charlson Comorbidity Index \[[@CR26]\]; the Instrumental Activities of Daily Living \[[@CR13]\], the Geriatric Depression Scale \[[@CR27]\], and the Short Form Health Survey \[[@CR28]\], and will be assessed at baseline, at 3 months, and 1 year postoperatively. Subjective grading of cognitive functions and subjective grading of pain are determined on numeric rating scales at baseline, 7 days, 3 months and 1 year postoperatively. Subjective grading of change in cognitive functions (five-point Likert scale) and subjective grading of successful surgery (yes/no) are assessed at 7 days, 3 months and 1 year postoperatively.

### Magnetic resonance imaging {#Sec12}

Cerebral MRI will be performed at baseline, at 3 months, and 1 year postoperatively on the same day as the neuropsychological assessment. MRI analysis will be carried out by the Division of Neuroradiology at the University Hospital Basel. High-resolution anatomic and diffusion cerebral MRI will be performed using the hospital's 3-Tesla MAGNETOM Prisma™ MRI scanner (Siemens, Zurich, Switzerland). For MRI analysis, we will assume that the same regions as those described in mild cognitive impairment and Alzheimer's disease \[[@CR29]\] are relevant to POCD. We will perform a region of interest (ROI) analysis (hippocampus, lateral ventricle, total grey matter volume, regional cortical thickness). Cortical reconstruction and volumetric segmentation will be performed with the FreeSurfer software suite \[[@CR30]\], which is freely available for download online (<http://surfer.nmr.mgh.harvard.edu>).

Statistics {#Sec13}
----------

### Sample size justification {#Sec14}

Sample size is estimated based on data describing hippocampal volume. The clinically relevant difference is defined as the difference in hippocampal volume between normal subjects (2.8 ± 0.5 cm^3^) and patients with mild cognitive impairment (2.4 ± 0.4 cm^3^) \[[@CR29]\]. Assuming an incidence of POCD of 41% one week after surgery in this age group \[[@CR2]\], and a standard deviation of the hippocampal volume change of 0.45 in both patients with and without POCD, a total sample size of 56 subjects may detect a difference of 0.4 cm^3^ in hippocampal volume \[[@CR29]\] with a power of 90% at a two-sided significance level of 5%. To compensate for the high loss to follow-up, which is unfortunately typical for studies on POCD \[[@CR31]\] and estimated at 20%, we will recruit 70 patients in the surgical group (Group 1). The number of study participants in the nonsurgical control group (Group 2) is arbitrarily set at 30.

### Statistical analysis plan {#Sec15}

The quantitative imaging results will be correlated to the CERAD-NAB total score performance obtained on the same day as the MRI scans. The relationship of changes in volume with intraoperative depth of anesthesia (BIS) and the administered dose of sevoflurane expressed as age-corrected minimum alveolar concentration (MAC) equivalent \[[@CR32]\] multiplied by time of administration will be calculated. We will use voxel-wise, multivariate analysis of variance (ANOVA) and the classification/prediction procedure on multi-parameter MRI data in order to build optimal composite predictors of patients' neuropsychological outcomes. All statistical analyses will be performed using SPSS Statistics software, version 22 (IBM, Inc., Zurich, Switzerland). All graphs will be plotted using Prism, version 6 (GraphPad Software, Inc., La Jolla, CA, USA). An interim analysis will be performed to assess quality of data after primary data acquisition from 20 participants. We will follow the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement \[[@CR33]\] for all future reports related to this study.

Data monitoring and stopping rules {#Sec16}
----------------------------------

The EC agreed that monitoring would be performed by the interdisciplinary study team. This team will evaluate the progress of the trial, verify the accuracy and completeness of the case report forms, and ensure that all protocol requirements and investigator's obligations are being fulfilled. The progress of the trial is evaluated every 6 months. The investigators may terminate the study prematurely according to certain circumstances (e.g., ethical concerns, insufficient participant recruitment, when the safety of the participants is doubtful or at risk, or when alterations in accepted clinical practice make the continuation of a clinical trial unwise).

Study safety and reporting of adverse events {#Sec17}
--------------------------------------------

There are no specific safety concerns related to this study. During initial screening of participants in the recruitment phase, any subject that presents potential safety concerns related to MRI will be excluded from the study. Above all, MRI does not use ionizing radiation, and there are no known harmful side-effects associated with temporary exposure to the strong magnetic field used by MRI scanners \[[@CR34]\]. However, if a serious adverse event should occur, it will be reported to the EC within the appropriate time frame.

Discussion {#Sec18}
==========

This observational cohort study prospectively evaluates the relationship of cerebral grey matter volume and POCD in elderly patients after major noncardiac surgery under sevoflurane anesthesia. The primary hypothesis of this investigation is that POCD is accompanied by a loss of cerebral grey matter. Our secondary hypothesis is that the degree of POCD correlates with the loss of grey matter in brain areas relevant for cognitive functions. There are several potential implications of this study for future clinical practice. The validation of reproducible anatomical parameters or biomarkers, such as the specific brain volumes examined in our cohort, will help to identify high-risk patients and may serve to evaluate the effect of preventive strategies and treatment interventions for POCD in clinical follow-up studies. In summary, findings of this study may contribute to improve the diagnosis and prevention of POCD in the future. In the following, we discuss considerations regarding study design, endpoints, choice of study collective, surgical procedures and anesthetic technique.

Study design {#Sec19}
------------

The cohort study design chosen for our study enables investigative research in a real-life clinical context without influencing state-of-the-art medical care of patients. No study-related intervention is planned in participating patients, and risks are minimal. Given the lack of clinical data and missing preventive and/or clinical treatment approaches towards POCD, our study is aimed to investigate an association between the cognitive decline and an anatomical biomarker. At this point, POCD research is limited to noninterventional clinical studies, hence the prospective observational design of this study.

Endpoints {#Sec20}
---------

The choice of radiological endpoints of our investigation is based on the findings of AddNeuroMed study \[[@CR29]\]. Liu et al. reported that the degree of atrophy in specific cortical areas correlates with the results of neuropsychological assessment tests obtained by subjects with various cognitive disorders (unrelated to surgery) \[[@CR29]\]. We assume that brain areas affected in POCD are comparable to those concerned in Alzheimer's disease or mild cognitive impairment.

Methodological considerations {#Sec21}
-----------------------------

### Choice of study collective {#Sec22}

Although POCD was described in middle-aged patients \[[@CR3]\], the disorder has its highest incidence among patients over the age of 65 years. As most research on POCD was done in this age group, we decided to set the cut-off for participant age at 65 years. We excluded subjects with conditions known to induce changes in cerebral anatomy such as Alzheimer's disease and other forms of dementia, a history of severe neurological disease, or chronic pain in order to obtain a patient sample free of pre-existing cognitive disorders that might confound the relationship between brain volumes and POCD. The addition of a group of nonsurgical participants serves to control for practice effects related to neuropsychological assessment, to observe the physiological cerebral atrophy rates in volunteers matched to the surgical group, and to establish a paradigm for further research on POCD.

### Choice of surgical procedures {#Sec23}

We carefully considered the range of surgical procedures to include in our study. We excluded cardiac surgery because of potential issues with cardiopulmonary bypass, surgery of the brain or extracranial blood vessels, and any type of surgery of the face or neck that would preclude patients' active participation in the postoperative neuropsychological assessments. Emergency procedures were also excluded, since we would be unable to measure the patient's baseline. At our institution, abdominal, gynecologic, urologic, vascular and orthopedic procedures are the most commonly performed major noncardiac surgeries in older adults. Most of these surgeries involve a hospital stay of at least 5 days. Although this study is monocentric, we strongly believe that the resulting study cohort is representative of a general surgical population.

### Choice of anesthetic technique {#Sec24}

In this study with pilot character, we chose to investigate exclusively Sevoflurane-based general anesthesia, in order to standardize anesthetic management as a measure to minimize bias. Sevoflurane anesthesia is delivered by the attending anesthetist primarily based on BIS targets (40--60) and clinical judgement. Given that the choice of anesthetic technique only marginally influences the risk of developing POCD in surgical patients \[[@CR35]\], we intend to examine the effect of other anesthetic drugs (e.g., propofol as total intravenous anesthesia) and other anesthetic techniques (e.g., neuraxial or regional anesthesia) on brain volumes and POCD in follow-up studies with similar research protocols. Airway management is standardized as all patients participating in this study are intubated and mechanically ventilated. Other aspects of intraoperative anesthetic management such as the use of opioids or muscle relaxants and hemodynamic management are left at the discretion of the attending physician following existing institutional guidelines.

### Diagnosis of POCD {#Sec25}

POCD is a complex neuropsychological disorder presenting as a decline in various cognitive domains after surgery and may at times be difficult to diagnose. Clinical cognitive outcomes research is complicated by the fact that there is no universal definition of POCD. Assessment for POCD comprises a time-intensive combination of neurocognitive function tests, and expert evaluation is mandatory for a valid diagnosis of POCD. In the literature, large differences in methodology (e.g., the test batteries used, the interval between sessions, the endpoints to be analyzed, statistical methods) and diagnostic criteria for POCD are apparent \[[@CR31]\]. In our study, the diagnosis of POCD is based on a decrease of standard scores in the CERAD-NAB.
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